To evaluate prevalence and clinical features of immune-related adverse events (irAEs) to immune checkpoint inhibitors (ICIs) in accordance with the gender of treated cancer patients.
Immune checkpoint inhibitors-induced autoimmunity: The impact of gender / Triggianese, P., Novelli, L., Galdiero, M.R., Chimenti, M.S., Conigliaro, P., Perricone, R., Perricone, C., Gerli, R.. - In: AUTOIMMUNITY REVIEWS. - ISSN 1568-9972. - 17:8(2020), p. 102590. [10.1016/j.autrev.2020.102590]
Immune checkpoint inhibitors-induced autoimmunity: The impact of gender
Triggianese, Paola;Galdiero, Maria Rosaria;
2020
Abstract
To evaluate prevalence and clinical features of immune-related adverse events (irAEs) to immune checkpoint inhibitors (ICIs) in accordance with the gender of treated cancer patients.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Triggianese et al Autoimmun Rev 2020.pdf
solo utenti autorizzati
Tipologia:
Documento in Post-print
Licenza:
Accesso privato/ristretto
Dimensione
387.93 kB
Formato
Adobe PDF
|
387.93 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
